Hormonal
A combined nutraceutical product containing Lagerstroemia speciosa, Berberis aristata, Curcuma longa, Alpha-lipoic acid, Chromium picolinate, and Folic acid significantly improves triglycerides, HDL-C, fasting plasma insulin, and HOMA-Index in patients with impaired fasting glucose over an 8-week period.
If you have impaired fasting glucose, a specific combination of plant extracts and micronutrients (Banaba, Berberine, Turmeric, Alpha-lipoic acid, Chromium, Folic acid) taken as two pills daily for 8 weeks, alongside standard dietary and exercise advice, may significantly improve your triglycerides, HDL cholesterol, and insulin resistance markers compared to placebo. This suggests it could be a useful tool for managing metabolic risk in pre-diabetic individuals, though long-term effects are not yet established.
After the nutraceutical treatment, and compared to the placebo-treated group, the enrolled patients experienced a significant improvement in TG (-34.7%), HDL-C (+13.7), FPI (-13.4%), and HOMA-Index (-25%) versus the baseline values.
Why this rating
The study is a randomized, double-blind, placebo-controlled trial, but it is a pilot study with a small sample size (N=40) and short duration (8 weeks).
Source
Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product
Arrigo F.G. Cicero et al. · High Blood Pressure & Cardiovascular Prevention · 2017
DOI 10.1007/s40292-017-0206-3
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →